



**EYEPOINT**  
PHARMACEUTICALS

Delivering Innovative Ophthalmic Products to  
Patients with Serious Eye Disorders

**Investor Presentation**

August 2019

NASDAQ: EYPT

# Forward Looking

**SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995:** Various statements made in this release are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. This presentation is intended for communication for investors only. Nothing in this presentation should be construed as promoting the use of YUTIQ®, DEXYCU® or other product candidates. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the future, including but not limited to statements about our commercialization of YUTIQ and DEXYCU, the potential for our products to alter the treatment landscape for ocular diseases; our expectations regarding the timing of our planned sNDA filing for our YUTIQ line extension shorter-acting treatment for non-infectious uveitis affecting the posterior segment of the eye; and the expected use of proceeds from our debt refinancing and equity offering and our expectation that the Company's existing cash and cash equivalents at June 30, 2019 and cash inflows from anticipated YUTIQ and DEXYCU product sales will be sufficient to fund our operating plan into 2020, are forward-looking statements. Some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements are risks and uncertainties inherent in our business including, without limitation: our ability to achieve profitable operations and access to needed capital; fluctuations in our operating results; our ability to successfully produce sufficient commercial quantities of YUTIQ and DEXYCU and to successfully commercialize YUTIQ and DEXYCU in the U.S.; our ability to sustain and enhance an effective commercial infrastructure and enter into and maintain commercial agreements for YUTIQ and DEXYCU; the regulatory approval and successful release of our YUTIQ line extension shorter-duration treatment for non-infectious uveitis affecting the posterior segment of the eye; potential off-label sales of ILUVIEN for non-infectious uveitis affecting the posterior segment of the eye; consequences of fluocinolone acetonide side effects for YUTIQ; consequences of dexamethasone side effects for DEXYCU; successful commercialization of, and receipt of revenues from, ILUVIEN for diabetic macular edema, or DME; Alimera's ability to obtain additional marketing approvals and the effect of pricing and reimbursement decisions on sales of ILUVIEN for DME; Alimera's ability to commercialize ILUVIEN for non-infectious uveitis affecting the posterior segment of the eye in the territories in which Alimera is licensed to do so; declines in Retisert royalties; our ability to market and sell products; the success of current and future license agreements; termination or breach of current license agreements; our dependence on contract research organizations, contract sales organizations, vendors and investigators; effects of competition and other developments affecting sales of products; market acceptance of products; effects of guidelines, recommendations and studies; protection of intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; industry consolidation; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; volatility of stock price; possible dilution; absence of dividends; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.



# EyePoint Highlights: Transformational Opportunity in Ophthalmology

---



Postoperative  
inflammation following  
ocular surgery



Chronic non-infectious  
uveitis affecting the  
posterior segment of the  
eye

---

Acquired Icon Bioscience to transform business and accelerate growth

---

---

Executing on strategy to commercialize our own products, expand our ophthalmology portfolio and utilize our existing technology platforms

---

---

Obtained \$80M+ from equity and debt partners in 2018

---

---

Established a strong leadership team with seasoned executives to lead our commercial strategy and manage our sales infrastructure

---

---

Launched **YUTIQ® (Feb 4, 2019)** and **DEXYCU® (Mar 12, 2019)**

*(Permanent and unique J code for DEXYCU now in place; permanent and unique J code for YUTIQ effective October 1, 2019)*


# Management with Proven Commercial Track Record & Highly Experienced Board of Directors




**Nancy Lurker**  
President and CEO



**Dario Paggiarino, M.D.**  
Chief Medical Officer



**Scott Jones**  
Chief Commercial Officer



**Said Saim, Ph.D.**  
Chief Technology Officer



## Board of Directors

**Dr. Göran Ando**  
Chairman of the Board

**Nancy Lurker**  
President and CEO

**Dr. Jay Duker**  
Director

**Ron Eastman**  
Director

**Doug Godshall**  
Director

**Dr. David Guyer**  
Director

**Dr. John Landis**  
Director

**Dr. David J. Mazzo**  
Director


**Kristine Peterson**  
Director

**Wendy DiCicco**  
Director

# Durasert™: Approved Technology for Ocular Delivery

- EyePoint is one of few companies that has developed FDA-approved extended-release inserts
- EyePoint will continue to evaluate potential partnerships that utilize Durasert technology







## Selected Major IVT Insert Approvals



## Durasert Attributes

- Proven in FDA-approved products
- Long duration (*can be tailored to last months to years*)
- Broadly applicable to small molecules
- Strong patent estate (2027 expiry)

# EyePoint Pharmaceuticals' Product Pipeline

Product / Program	Preclin.	Phase 1	Phase 2	Phase 3	Approval	Market	Rights
<b>DEXYCU®</b> post-operative inflammation					J-Code Received	Launched Mar 12, 2019	WW
<b>YUTIQ®</b> three-year treatment for chronic non-infectious uveitis affecting the posterior segment					J-Code Received (effective October 1, 2019)	Launched Feb 4, 2019	U.S. <sup>(1)</sup>
<b>YUTIQ®</b> shorter duration treatment for chronic non-infectious uveitis affecting the posterior segment					sNDA filing 2019		WW
<b>Durasert™ TKI</b> wet AMD							WW
<b>ILUVIEN®, RETISERT®</b> Royalties							Partners <sup>(1)(2)</sup>
<b>Collaborations</b>							Partners <sup>(3)</sup>

(1) Alimera Sciences, Inc. owns worldwide rights to ILUVIEN® for DME and rights for YUTIQ® for non-infectious posterior uveitis in the EMEA.

(2) RETISERT® (fluocinolone acetonide intravitreal implant), for posterior uveitis, is licensed to and sold by Bausch & Lomb, Inc.

(3) EyePoint is currently engaged in a collaboration relating to a back of the eye disease. EyePoint will continue to evaluate other potential technology platform agreements.

# DEXYCU® & YUTIQ® Commercialization Roadmap

---

## Medical Education Plan Rolled Out


- ✓ Multiple KOL Advisory Boards & significant presence at key congresses
- ✓ Robust publication plan and key papers published with continued data flow
- ✓ MSL team complete

## Contract Sales Organization in Place (43 reps in total)

- ✓ Dedicated sales team has been interviewed and chosen by EyePoint Management
  - ✓ 33 Key Account Managers (KAMs) focused exclusively on DEXYCU®
  - ✓ 10 KAMs focused exclusively on YUTIQ®
- ✓ KAMs and back office support managed by CSO
- ✓ National Sales Director and DMs employed by EyePoint

## Payor and Reimbursement Team in Place

- ✓ Dedicated team in place
- ✓ Reimbursement support services will be provided
  - ✓ J-Code (J1095) received for DEXYCU®
  - ✓ J-Code (J7314) received for YUTIQ® (effective October 1, 2019)
- ✓ Third party logistics (3PL) in place
- ✓ EyePoint Assist launched



**DEXYCU<sup>®</sup>**


(dexamethasone intraocular  
suspension) 9%

## **Postoperative inflammation following ocular surgery**



# DEXYCU® Market

- A cataract is a clouding of the lens in the eye that affects vision
- Cataract surgery is an intervention whereby the clouded lens is removed and replaced with an artificial intraocular lens (IOL)



- Patients can experience post-operative ocular inflammation following a cataract procedure

**4.8 Million\***


**Cataract surgeries  
per year**

- 8% annual growth rate in the U.S.
- Most performed surgery in the U.S.

- *Baby boomers; longer life expectancy*
- *Improvements to intraocular lenses (IOLs)*
- *Experienced surgeons*

\* Based upon company estimates for 2018.  
Source: imaged from the American Optometric Association.

# Current Post-Cataract Regimen Requires Polypharmacy and Places Significant Burden on Patients and Physician Offices



**Up to 100 Drops Over Four Weeks**

## PHYSICIAN PERSPECTIVE

**POOR PATIENT COMPLIANCE WITH DROP REGIMEN COULD LEAD TO POOR OUTCOMES**

**SIGNIFICANT NUMBER OF PATIENT CALL BACKS ARE TIME CONSUMING AND DISRUPTIVE TO OFFICE**

**PATIENTS/CAREGIVERS ARE FRUSTRATED AND CONFUSED WITH REGIMEN IMPACTING SATISFACTION**

\* Source: Vigamox/Besivance product labeling (not specifically indicated for this use, but are commonly prescribed for use).

\*\* Source: Prolensa/Bromday product labeling (not specifically indicated for this use, but are commonly prescribed for use).

# DEXYCU® (dexamethasone intraocular suspension) 9% is indicated for the treatment of postoperative inflammation

*First and only FDA-approved single-dose, sustained-release, intracameral steroid for the treatment of postoperative inflammation following ocular surgery*


- Single dose (5 $\mu$ L) administered in the posterior chamber (behind the iris) at the end of surgery
- Encapsulated in bioerodible Verisome® technology for extended release of dexamethasone

## Verisome® Technology




Detectable up to 22 days after single injection<sup>(1)</sup>

## DEXYCU® Kit



## DEXYCU® Placement




Suspension placed behind the iris

(1) Wong V. et al. Pharmacokinetic Study of 10090 in the Anterior Chamber of Rabbits (2013).  
Note: Refer to the full DEXYCU® product label at [www.eyepointpharma.com](http://www.eyepointpharma.com).


# DEXYCU® Rapidly Reduces Inflammation as Early as Day 1 with Statistical Significance at Day 3 through Day 30

## Patients with Anterior Chamber Cells (ACC) Clearing at Each Visit




# Difference in IOP Elevation Between DEXYCU® and Placebo Not Clinically Significant


## IOP Intervals on POD 1




## IOP Intervals on POD 3



## IOP Intervals on POD 8



## IOP Intervals on POD 15



# Phase 3 Study 13-04 Safety Results

Safety, n (%)	Placebo N=80	517 mcg N=156
Any TEAE in study eye	51 (63.8)	72 (46.2)
Any ocular SAE in study eye	0	0
Any non-ocular SAE	4 (5.0)	4 (2.6)
Study Eye AEs Occurring in $\geq 5\%$ of At Least One Active Treatment Group		
Intraocular pressure increased	7 (8.8)	21 (13.5)
Corneal edema	8 (10.0)	12 (7.7)
Eye pain	7 (8.8)	4 (2.6)
Anterior chamber inflammation	10 (12.5)	8 (5.1)
Dry eye	0	6 (3.8)

# DEXYCU® Commercial Launch Approach

*Launched on March 12, 2019*

**33 KAMs**

*solely focused  
on DEXYCU®*

**1,000 ASCs**

*Ambulatory surgical  
centers that perform  
>500 surgeries/year*

**J-Code**

*Reimbursement in  
place*

- Specific and permanent J-code issued for Medicare and Commercial payor use
- Pass-through Medicare reimbursement for ~3 years post commercialization
- Exploring pathway to extended pass-through reimbursement within Medicare Part B


**We believe that DEXYCU®  
has the potential to benefit  
multiple stakeholders due to  
its unique formulation**

- ✓ *Suppresses inflammation*
- ✓ *Offsets eyedrop burden / limits potential patient confusion*
- ✓ *Patients typically required to pay out of pocket for eyedrops*
- ✓ *Ease of use / non-disruptive to existing surgical practice*
- ✓ *Potential improvement in compliance*

# DEXYCU® Market Research


*Market Survey Involving Over 100 Cataract Surgeons Shows High Intent To Use*

## Indicated Intent to Use




86% indicated intent to use

## Appropriate Patient Population



72% of patients would be appropriate candidates\*

## Likelihood to Recommend



87% would recommend to a colleague upon commercial availability





# DEXYCU® Launch Progress Update

*Data as of August 7, 2019*

---

## Phased Launch Program

- **33** KAMs dedicated to the promotion of DEXYCU have focused on a phased launch program to ensure proper physician training for the preparation, application and administration of DEXYCU
- Over **400** surgeons in more than **275** ASCs have completed the training/certification program and are now able to purchase DEXYCU
- **4,200+** patients have been injected with DEXYCU (via sampling program)
- **3,000+** medical professionals and office staff have been called on to discuss DEXYCU

## Reimbursement

- During the initial months following our launch of DEXYCU, we have observed the positive adjudication of the vast majority of commercial, Medicare Advantage and Medicare fee for service claims
  - Observations are based on claims shared with us by accounts and/or through our HUB, and that Medicare has consistently covered all in-label uses of DEXYCU






## **Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye**

# YUTIQ® Market

- Uveitis is inflammation of the uveal tract (iris, ciliary body, choroid) or adjacent structures (lens, retina, vitreous, optic nerve)
- Uveitis can be acute or chronic and the flares of inflammation and swelling can lead to severe vision loss and blindness
- Chronic non-infectious posterior segment uveitis impacts the posterior segment of the eye, often involving the retina, and is a leading cause of blindness in developed countries



**~55K-120K**

**Patients in the U.S. with chronic non-infectious posterior segment uveitis**

- Sight-threatening inflammatory disease
- ~30,000 new cases of blindness per year in the U.S.


# YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg for chronic non-infectious uveitis affecting the posterior segment of the eye

---

- Chronic non-infectious posterior segment uveitis is treated both aggressively and frequently by physicians in order to minimize the disease flares
- Periocular and intravitreal steroid injections, and systemic delivery of corticosteroids are routinely used to treat chronic non-infectious posterior segment uveitis
- The current standard of care treatment provides sustained release of steroids over a period of 3 to 4 months


YUTIQ provides consistent micro dosing of corticosteroid **up to three years** without drug peaks and valleys and has been shown to significantly decrease the **recurrence of flares**

↓  
*primary goal  
of therapy in uveitis*




# Primary Efficacy Endpoint: Recurrence Rate at 6 and 12 Months

## Study 1 (Recurrence Rate at 6 and 12 Months)



## Study 2 (Recurrence Rate at 6 and 12 Months)




\* Sham includes standard of care.

Note: Refer to the full YUTIQ® product label at [www.eyepointpharma.com](http://www.eyepointpharma.com)



# Reduced Probability of Uveitis Recurrence Through 36 Months After a Single YUTIQ® FA Insert (STUDY PSV-FAI-001)

## ITT Population



**YUTIQ median time to first recurrence: 1051 days**

**3 years**

Note: Sham patients include patients that received rescue therapy.

# YUTIQ® Safety: Selected Ocular Adverse Events

Safety, n (%)	YUTIQ™ n=226	Placebo n=94
Visual Acuity Reduced	33 (15%)	11 (12%)
Macular Edema <sup>1</sup>	25 (11)	33 (35)
Uveitis	22 (10)	33 (35)
Conjunctival Hemorrhage	17 (8)	5 (5)
Eye Pain <sup>2</sup>	17 (8)	12 (13)
Hypotony of the Eye <sup>3</sup>	16 (7)	1 (1)
Anterior Chamber Inflamm.	12 (5)	6 (6)
Dry Eye	10 (4)	3 (3)

(1) Includes macular edema and cystoid macular edema

(2) Includes eye pain and procedural pain

(3) Includes hypotony, intraocular pressure decreased and procedural hypotension

Note: Refer to the full YUTIQ® product label at [www.eyepointpharma.com](http://www.eyepointpharma.com)

# YUTIQ® Commercial Launch Approach

*Launched on February 4, 2019*

## 10 KAMs

*solely focused  
on YUTIQ®*

**Consistent  
micro-dosing of  
corticosteroid  
over time without  
drug peaks and  
valleys**

## J-Code

*Effective October 1,  
2019*

- Specific and permanent J-code issued for Medicare and Commercial payor use, effective October 1, 2019

**We believe that YUTIQ® fits naturally into the current treatment paradigm for chronic NIPU and provides physicians with a differentiated alternative to existing therapies**


- ✓ *Longest duration product indicated for chronic non-infectious uveitis*
- ✓ *Non-disruptive / corticosteroids remain current standard of care*
- ✓ *Goal of treatment is to prevent flares that can lead to blindness*



# YUTIQ® 6mo vs. 3yr Implant *in Vitro* Release Rate Comparison

- Potential approval of 6-month duration YUTIQ® could expand the YUTIQ® franchise and enable physicians more flexibility
- sNDA filing planned in 2019

Long term *in vitro* release rate matched with the 3-year insert



Note 1: Study conducted in rabbit eyes.

Note 2: Release rate compared to rate meeting specifications for stability of clinical lot used in Iluvien clinical trials at pre-determined time points (in orange).

# YUTIQ® Launch Progress Update

*Data as of August 7, 2019*

---

## Launch Program

- **10** KAMs are dedicated to calling predominantly uveitis specialists across the U.S.
- **95%** of the top decile uveitis specialists have been visited by KAMs
- YUTIQ has been included in more than **20** Academic Formularies and is pending inclusion for an additional **8**

## Reimbursement

- During the initial months following our launch of YUTIQ, we have observed the positive adjudication of the vast majority of commercial, Medicare Advantage and Medicare fee for service claims
  - Observations are based on claims shared with us by accounts and/or through our HUB, and that Medicare has consistently covered all in-label uses of YUTIQ

# Company Milestones & Strategy

---

- DEXYCU® launched on March 12, 2019
  - YUTIQ® launched February 4, 2019
- 
- YUTIQ® 6-month formulation sNDA submission in 2019
  - Continued development and progression of Durasert™ TKI
  - Potential partnerships surrounding Durasert™ and Verisome® technologies
  - Evaluating in-licensing and M&A opportunities
  - Exploring pathway to extended reimbursement outside of cataract bundle within Medicare Part B

# Financial Highlights

---

<b>Cash</b>	<b>\$44.2 million as of June 30, 2019</b>
<b>Debt</b>	<b>Up to \$60.0 million facility with CRG Servicing LLC</b> <ul style="list-style-type: none"><li>• \$35.0 million drawn in February 2019</li><li>• \$15.0 million drawn in April 2019 to fund milestone payment to former Icon Bioscience security holders following first commercial sale of DEXYCU</li></ul>
<b>Shares Outstanding</b>	<b>106 million common shares as of August 5, 2019</b>

Note: Please refer to the Company's filings on EDGAR for further detail.

# EyePoint Highlights: Transformational Opportunity in Ophthalmology

---



Postoperative  
inflammation following  
ocular surgery



Chronic non-infectious  
uveitis affecting the  
posterior segment of the  
eye

---

Acquired Icon Bioscience to transform business and accelerate growth

---

---

Executing on strategy to commercialize our own products, expand our ophthalmology portfolio and utilize our existing technology platforms

---

---

Obtained \$80M+ from equity and debt partners in 2018

---

---

Established a strong leadership team with seasoned executives to lead our commercial strategy and manage our sales infrastructure

---

---

Launched **YUTIQ® (Feb 4, 2019)** and **DEXYCU® (Mar 12, 2019)**  
(Permanent and unique J code for DEXYCU now in place; permanent and unique J code for YUTIQ effective October 1, 2019)